BELLRING BRANDS, INC. (BRBR) stock intrinsic value fair value estimate & owner earnings analysis

BellRing Brands sells protein nutrition products. Premier Protein, mostly ready-to-drink shakes plus powders, was 85.9% of fiscal 2025 net sales and Dymatize sports powders 12.1%. Nearly everything is made by outside contract manufacturers, so capital spending is tiny (about $2 to $5 million a year; about $10 million expected for fiscal 2026). Walmart (including Sam's Club), Costco and Amazon together bought 74.0% of fiscal 2025 net sales, and 88.1% of sales are in the United States. Net sales grew every year, from $988 million in fiscal 2020 to $2,317 million in fiscal 2025, and the company has reported positive net earnings in every year on record (about $216 million in fiscal 2025 and $111.8 million in the first nine months of fiscal 2026). Two features of the balance sheet matter. First, the company has little in the way of hard assets: total assets were $1.05 billion at June 30, 2026, mostly inventory ($480.6 million) and receivables ($216.3 million), with goodwill and brand intangibles only about $178 million combined. Its value is the earning power of Premier Protein and its retail relationships, not property. Second, stockholders' equity is negative ($467.2 million deficit) because the company borrowed to buy back shares (treasury stock of $910.1 million), not because it has lost money. What has changed in the business: profits dropped sharply in fiscal 2026. In the first nine months net sales rose 2.3% ($1,706 million versus $1,668 million), but gross margin fell to 28.5% from 34.9% as whey and milk-protein costs, tariffs and freight rose and promotions increased (shake price/mix was down 4.7% over the nine months). Shake volume was up 5.2% over the nine months and Premier Protein shake dollar consumption at retail was up 6.0% in the June quarter, so end demand has not collapsed; the problem is margin. The company took $21.3 million of inventory charges (an $11.3 million ingredient that failed quality requirements and a $10.0 million write-down of excess shake bottle inventory) and expects about $7 million more in the fourth quarter. Nine-month net earnings were $111.8 million versus $156.6 million a year earlier, and the earlier figure already carried a $69.0 million Joint Juice settlement charge, so the underlying fall is larger. Michael Axelrod became chief executive on July 29, 2026, and a reorganization announced in June is expected to save $10 to $12 million a year before tax. A double-digit price increase on Premier Protein shakes takes effect in the first quarter of fiscal 2027; management expects volume to fall by slightly more than the price rises. We count no benefit from it, because it has not happened and the volume response is untested. Since our previous estimate we found three things we had not counted: (1) fiscal 2026 gross profit includes $31.1 million of gains on commodity hedges that the company describes as primarily non-cash and not recurring; because they reflect higher protein costs that will hit the income statement later, we do not treat them as part of normal earnings (about $24 million after tax); (2) the company has $1,362.9 million of purchase commitments running through fiscal 2033 ($602.7 million due in fiscal 2026) while inventory has risen 45% since September 2025 on sales growth of about 2%, which raises the risk of further write-downs if volume falls; and (3) securities class actions were filed starting in January 2026 on behalf of investors who bought between November 19, 2024 and August 4, 2025, alleging that sales growth in that period reflected retailers stockpiling inventory. These are allegations, not findings, and consumption data for the latest quarter does not point to a collapse in end demand, so we count nothing in the base or bull cases and a modest amount in the bear case. Our earlier figures were prepared with these items left out; our new figures are lower in the base and bear cases and about unchanged in the bull case. What the company owes: about $1.14 billion, made up of $840 million of 7.00% senior notes due March 15, 2030 and roughly $300 million drawn on a $500 million revolving credit facility maturing August 22, 2030 (December 14, 2029 if the notes have not been refinanced or repaid by then). Interest is running at about $80 million a year. The loan agreement limits net debt to 6.0 times earnings as defined there; management put the figure at 3.2 times at June 30 and expects about 4 times at fiscal year-end, mainly because the $90.0 million Joint Juice settlement ($19.2 million New York and $70.8 million multistate) is expected to be paid in the fourth quarter. We deduct about $69 million for that settlement, after its expected tax deduction. Because the 7.00% notes cost about one point more than ordinary borrowing until 2030, we add about $26 million; we also credit $25 million of cash beyond operating needs. Net, the company owes about $1.21 billion in the base and bull cases. There are 116.6 million diluted shares. How we measure earnings: the cash the business generates before paying lenders, after taxes, stock compensation and necessary capital spending, with working-capital swings removed. On that basis it produced about $196 million in fiscal 2022, $254 million in 2023, $335 million in 2024 and $279 million in 2025 ($348 million without the settlement charge, which is not a recurring cost). For fiscal 2026 we estimate about $231 million as reported, or about $235 million after removing the hedge gains ($24 million) and adding back the inventory charges and reorganization costs that should not repeat (about $28 million after tax). The five-year median of fiscal 2022 to 2026 is about $254 million, spanning one full protein-cost cycle. We set the base below that median, at $240 million, because three consecutive quarters now show the lower margin level and the fiscal 2024 and 2025 results rested on protein costs that have reversed. Fiscal 2025 earnings fell 16.5% as reported (they rose about 4% before the settlement charge); our estimate for fiscal 2026 is about 17% lower again. The base case's first year, $240 million, is 14% below fiscal 2025 as reported and about 4% above our fiscal 2026 estimate; the rise over fiscal 2026 has dated reasons: the inventory charges recorded in the March and June 2026 quarters and the June 2026 reorganization costs do not repeat, and the headcount reductions already announced add about $8 million a year after tax, partly offset by removing the hedge gains. Acquired brand and customer intangibles amortize about $17 million a year; that is non-cash and is added back, but because we hold earnings flat and then fade them rather than grow them, we do not treat those assets as permanent. Base case: $240 million a year for ten years with no growth credited, because share gains, new distribution, the price increase and margin recovery are not yet secured; buybacks are not counted. After year ten earnings fade 5% a year: the brand and its retail relationships have lasted through seven straight years of sales growth, but customer concentration and supply concentration (46.3% of Premier Protein shake supply comes from one manufacturer and 28.0% from a single facility) limit how long that can be assumed. The business is worth about $2.92 billion, it owes about $1.21 billion, leaving $1.71 billion, or $14.70 per share. Bear case: this combines the kind of cost squeeze the company has been through (gross margin fell to 30.8% in fiscal 2022 and is 28.5% now, or 26.6% before hedge gains) with a demand-side loss. Gross margin holds near 24.5% for three years, about two points below today's, and one of the three big retailers cuts back or the price increase costs more volume than expected, so sales settle about 10% lower at roughly $2.1 billion. That takes about $139 million of gross profit, or roughly $105 million after tax, out of today's level, so business cash earnings fall to about $140 million for three years, then recover to about $175 million (gross margin of about 27%) for years four to ten and fade 10% a year afterwards. In addition, excess inventory and purchase-commitment shortfalls cost about $38 million after tax over two years and the securities suits cost about $11 million after tax. Leverage would be about 6.4 times in the first year against the 6.0 times limit, so we assume a covenant amendment (about $20 million), and the 2030 notes are refinanced at about 9% for seven years, which adds about $141 million to the cost of the debt. The business still covers its roughly $80 million of annual interest, but with little room. The business is worth about $1.70 billion, it owes about $1.34 billion, leaving $0.36 billion, or $3.04 per share. Bull case: the announced price increase sticks with volume loss near what management expects and cost pressure eases the way it did after fiscal 2022, when gross margin recovered from 30.8% to 35.4% by fiscal 2024; gross margin returns to about 33% (fiscal 2025 was 33.3%) and the announced savings are kept. Cash earnings are $330 million a year for ten years, close to fiscal 2024's $335 million, then fade 3% a year. The business is worth about $4.42 billion, it owes about $1.21 billion, leaving $3.21 billion, or $27.49 per share. What would make this wrong: each $10 million a year of lasting cash earnings is worth about $1.04 per share, so the margin outcome matters most. At $190 million a year the shares would be worth about $9.50, and at $175 million about $7.90. Loss of volume at Costco, Walmart or Amazon, a supply problem at the main contract manufacturer, a larger-than-expected volume loss from the price increase, further write-downs of the inventory build, or a new round of competitive price cutting would push toward the bear case; a price increase that holds with modest volume loss would push toward the bull. We could not read the quarterly filing text, so fiscal 2026 figures come from its financial-statement data and the company's results release; we could not confirm which cash-flow line carries the hedge gains or split the margin decline by cause beyond what the company states, and the full fiscal 2026 numbers are estimates until the annual report is filed. Margin-of-safety price of $7.00: we are moderately sure of the earnings level. Three quarters show the weaker margin, but a new chief executive, an untested price increase, a 45% larger inventory balance and open securities suits leave a plausible range of roughly $175 to $300 million. The worst plausible outcome is a retailer cutback, a shake supply disruption and write-downs arriving together while debt is near 4 times earnings; the business has little hard-asset backing, so lenders' $1.2 billion claim rests on the brand's earning power. The 6.0 times limit and the 2030 maturities would likely survive the bear case with amendments, but not a worse outcome we have not modelled, such as a product recall or a major retailer replacing Premier Protein with its own brand. If we are wrong about the earnings level by $50 million a year, the shares would be worth about $9.50. The company pays no dividend, but at about $240 million of cash earnings it keeps roughly $160 million a year after interest, about $1.37 per share, which pays down debt over the holding period; the price assumes a two-to-three-year holding period. From $7.00 the $190 million case alone implies a value of about $11 after two and a half years, close to 20% a year, so that is the margin-of-safety price.